

# Simona Guerzoni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2197901/publications.pdf>

Version: 2024-02-01

44  
papers

1,249  
citations

471061

17  
h-index

360668

35  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1612  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. <i>Neurological Sciences</i> , 2022, 43, 1273-1280.	0.9	28
2	Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study. <i>Pain Medicine</i> , 2022, 23, 396-402.	0.9	5
3	Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. <i>Neurological Sciences</i> , 2022, 43, 3823-3830.	0.9	11
4	Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. <i>Cephalalgia</i> , 2022, 42, 645-653.	1.8	20
5	Occlusal splint therapy in patients with MÃ©niÃ©re's disease and temporomandibular joint disorder. <i>Acta Otorhinolaryngologica Italica</i> , 2022, , 1-8.	0.7	1
6	Clinical Evidence of Cannabinoids in Migraine: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1479.	1.0	7
7	Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. <i>Journal of Headache and Pain</i> , 2022, 23, 38.	2.5	18
8	The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine. <i>Neurological Sciences</i> , 2022, 43, 5687-5695.	0.9	8
9	Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. <i>Pain and Therapy</i> , 2021, 10, 637-650.	1.5	12
10	Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic. <i>Frontiers in Neurology</i> , 2021, 12, 647995.	1.1	5
11	Predictors of response to erenumab after 12 months of treatment. <i>Brain and Behavior</i> , 2021, 11, e2260.	1.0	34
12	Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients. <i>Pain and Therapy</i> , 2021, 10, 1605-1618.	1.5	8
13	Gender Differences in 3-Month Outcomes of Erenumab Treatmentâ€”Study on Efficacy and Safety of Treatment With Erenumab in Men. <i>Frontiers in Neurology</i> , 2021, 12, 774341.	1.1	14
14	A case-control study of visually evoked postural responses in childhood with primary headaches. <i>Neurological Sciences</i> , 2020, 41, 305-311.	0.9	4
15	Nummular headache: a gender-oriented perspective on a case series from the RegistRare Network. <i>Neurological Sciences</i> , 2020, 41, 583-589.	0.9	7
16	Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study. <i>Cephalalgia</i> , 2020, 40, 1070-1078.	1.8	6
17	Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data. <i>Journal of Headache and Pain</i> , 2020, 21, 40.	2.5	22
18	Nabilone administration in refractory chronic diarrhea: a case series. <i>BMC Gastroenterology</i> , 2019, 19, 105.	0.8	13

#	ARTICLE	IF	CITATIONS
19	Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication-overuse headache. BMC Neurology, 2019, 19, 239.	0.8	3
20	Easy tools to screen Italian women suffering from migraine with and without aura in early reproductive age. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 242, 63-67.	0.5	3
21	Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 189-198.	1.5	19
22	&lt;p&gt;Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy&lt;/p&gt;. Therapeutics and Clinical Risk Management, 2019, Volume 15, 557-569.	0.9	6
23	Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review. Pharmacological Research, 2018, 133, 65-76.	3.1	30
24	Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. Frontiers in Neurology, 2018, 9, .	1.1	0
25	Rare primary headaches in Italian tertiary Headache Centres: Three year nationwide retrospective data from the RegistRare Network. Cephalalgia, 2018, 38, 1429-1441.	1.8	9
26	Response to: "Drugs for treatment for alcohol use disorders expose to interactions with others" for little benefit if any. Pharmacological Research, 2018, 134, 220.	3.1	0
27	Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study. European Journal of Clinical Pharmacology, 2018, 74, 1427-1436.	0.8	27
28	Serum protein changes in a rat model of chronic pain show a correlation between animal and humans. Scientific Reports, 2017, 7, 41723.	1.6	26
29	Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clinical Pharmacology in Drug Development, 2017, 6, 534-547.	0.8	56
30	Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. Journal of Headache and Pain, 2017, 18, 71.	2.5	34
31	A Critical Evaluation on MOH Current Treatments. Current Treatment Options in Neurology, 2017, 19, 32.	0.7	17
32	Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. Frontiers in Neurology, 2017, 8, 586.	1.1	42
33	A genome-wide analysis in cluster headache points to neprilysin and PACAP receptor gene variants. Journal of Headache and Pain, 2016, 17, 114.	2.5	38
34	Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. Journal of Headache and Pain, 2016, 17, 48.	2.5	49
35	Validation of potential candidate biomarkers of drug-induced nephrotoxicity and allodynia in medication-overuse headache. Journal of Headache and Pain, 2015, 16, 559.	2.5	14
36	Proteomic research of proteins involved in pain expression in an animal model of chronic pain. Journal of Headache and Pain, 2015, 16, A8.	2.5	0

#	ARTICLE	IF	CITATIONS
37	Impact of continuing or quitting smoking on episodic cluster headache: a pilot survey. <i>Journal of Headache and Pain</i> , 2013, 14, 48.	2.5	35
38	Discovery by a proteomic approach of possible early biomarkers of drug-induced nephrotoxicity in medication-overuse headache. <i>Journal of Headache and Pain</i> , 2013, 14, 6.	2.5	15
39	Comparison of tolerability and efficacy of a combination of paracetamol+caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study. <i>Journal of Headache and Pain</i> , 2012, 13, 669-675.	2.5	22
40	Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. <i>Journal of Headache and Pain</i> , 2012, 13, 677-684.	2.5	67
41	Proteomic analysis of urine in medication-overuse headache patients: possible relation with renal damages. <i>Journal of Headache and Pain</i> , 2012, 13, 45-52.	2.5	15
42	Basal cutaneous pain threshold in headache patients. <i>Journal of Headache and Pain</i> , 2011, 12, 303-310.	2.5	30
43	Paracetamol: New Vistas of an Old Drug. <i>CNS Neuroscience &amp; Therapeutics</i> , 2006, 12, 250-275.	4.0	460
44	Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 981-1007.	1.5	9